Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to acquire Numab Therapeutics' subsidiary for global rights to NM26, a Phase 2-ready bispecific antibody.
This $1.25 billion all-cash deal focuses on NM26, which targets IL-4Rα and IL-31 pathways in atopic dermatitis (AD). NM26 aims to address unmet needs in AD by offering a unique treatment for inflammation and itch.
The transaction is expected to close in the second half of 2024, pending regulatory clearance. Johnson & Johnson plans to develop more bispecific antibodies for AD and other immune-mediated diseases.
Johnson & Johnson (JNJ) has announced its acquisition of Proteologix, a biotechnology firm specializing in bispecific antibodies for immune-mediated diseases, for $850 million in cash, with additional milestone payments possible. Proteologix's pipeline includes PX128, entering Phase 1 trials for moderate to severe atopic dermatitis (AD) and asthma, and PX130, in preclinical development for AD. These therapies target IL-13, TSLP, and IL-22 pathways, aiming to deliver superior efficacy and patient convenience.
The acquisition aligns with JNJ's strategy to enhance its dermatology portfolio and address significant unmet needs in AD treatment. Proteologix's assets offer potential best-in-disease efficacy by targeting multiple disease pathways, addressing heterogeneous disease-driving factors in diverse patient populations.
Kenvue (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of common stock at $20.00 per share, expected to close on May 17, 2024.
Kenvue will not sell any shares or receive proceeds from the offering. Instead, Johnson & Johnson (NYSE: JNJ) is expected to exchange these shares for its indebtedness held by Goldman Sachs & Co. and J.P. Morgan, who will then sell the shares to underwriters.
Post-offering, Johnson & Johnson will no longer own any shares of Kenvue. The offering will be managed by Goldman Sachs, J.P. Morgan, BofA Securities, and others. A registration statement on Form S-1 has been filed and declared effective by the SEC.
Kenvue Inc. (NYSE: KVUE) has announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. The offering involves the exchange of shares between Kenvue and Johnson & Johnson, with Goldman Sachs & Co. and J.P. Morgan acting as selling shareholders. Following the exchange, the selling shareholders will sell the shares to underwriters. Johnson & Johnson will no longer own any shares of Kenvue's common stock after the completion of the offering.
Johnson & Johnson (JNJ) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, with key executives Jennifer Taubert and John Reed representing the company. The event will take place on June 12th at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors and interested parties can access the live webcast on the company's website. The audio webcast replay will be available after 48 hours.
Johnson & Johnson announced a Plan of Reorganization by its subsidiary, LLT Management , to resolve 99.75% of talc claims related to ovarian cancer through a consensual approach. The Plan commits to paying $6.475 billion to claimants over 25 years, far better than trial recovery. The Company stands by the safety of its talc products amidst meritless litigation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.